Crescent Biopharma Grants 24,600 Options to Two Employees

Crescent Biopharma announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 24,600 shares of the Company's ordinary shares to two non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended. The options were approved on February 17, 2026 and were material to each employee's acceptance of employment with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4). The options were granted with a 10-year term and an exercise price equal to $9.33, the closing price per share of Crescent's ordinary shares as reported by Nasdaq on February 17, 2026. The options granted to each employee shall vest and become exercisable as to one-fourth of the shares subject to the respective options on the first anniversary of the employee's start date, and one-forty-eighth of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Crescent through the applicable vesting dates. The options are subject to the terms of the Inducement Plan and the terms and conditions of an option agreement covering the applicable grant.